Medtronic has received CE Mark approval for its Vitalis portfolio of five pacemakers, including a device designed for patients who may benefit from cardiac resynchronisation therapy (CRT) but in whom effective treatment using conventional biventricular pacing cannot be achieved. The portfolio comprises ReSyncra CSP, Restoria CSP, Refina CSP, Effectra and Confirma pacemakers, offering a range […]
The post Medtronic secures CE Mark for new cardiac pacing portfolio appeared first on Pharmafile.